Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jack Armstrong

Allergy & Immunology Mechanicsburg, PA Medical Doctor

NPI 1972569911 CMS profile 271170

1700 Bent Creek Blvd Ste 210, Mechanicsburg, PA 17050

Open in the dashboard

General payments

$84,609

1,208 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jack Armstrong of Mechanicsburg, PA is reported in the CMS Open Payments database as having received $84,609 across 1,208 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,351 161
2024 General $60,509 258
2023 General $10,198 196
2022 General $3,461 211
2021 General $3,101 157
2020 General $1,979 107
2019 General $2,010 118

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jack Armstrong
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Jack Armstrong were reported at $3,351. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Jack Armstrong Allergy & Immunology median Middle half National median
2019 $2,010 $594 $163–$1,512 $163
2020 $1,979 $426 $106–$1,233 $114
2021 $3,101 $638 $157–$1,708 $132
2022 $3,461 $790 $205–$1,961 $149
2023 $10,198 $852 $220–$2,147 $160
2024 $60,509 $865 $203–$2,267 $164
2025 $3,351 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $67,662 313 payments
  2. GlaxoSmithKline, LLC. $2,978 219 payments
  3. Regeneron Healthcare Solutions, Inc. $2,377 119 payments
  4. Genzyme Corporation $1,393 78 payments
  5. Pfizer Inc. $1,356 92 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $1,114 48 payments
  7. Genentech USA, Inc. $886 28 payments
  8. OptiNose US, Inc. $756 29 payments
  9. Grifols USA, LLC $717 34 payments
  10. AbbVie, Inc. $685 37 payments
  11. Other $4,684 211 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $59,850 29 payments
  2. Food and Beverage $23,030 1,148 payments
  3. Travel and Lodging $1,478 24 payments
  4. Education $250 7 payments
Products named General payments · program years 2019–2025
  1. AIRSUPRA $63,251 95 payments
  2. DUPIXENT Immunology $2,277 127 payments
  3. DUPIXENT Inflammation And Immunology $1,699 88 payments
  4. FASENRA $1,667 74 payments
  5. TRELEGY ELLIPTA $1,325 113 payments
  6. BREZTRI $1,143 39 payments
  7. NUCALA $908 68 payments
  8. Xolair $802 27 payments
  9. TEZSPIRE $792 34 payments
  10. Xhance $756 29 payments
  11. Other $12,788 647 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

860

Median for Allergy/ Immunology: 449

Drug cost

$336,764

Median for Allergy/ Immunology: $169,700

Branded share of claims

47.6%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 90 $82,586
Xolair Omalizumab Brand 25 $70,414
Dupixent Syringe Dupilumab Brand 15 $57,979
Breo Ellipta Fluticasone/Vilanterol Brand 58 $41,492
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 21 $20,854
Spiriva Respimat Tiotropium Bromide Brand 14 $12,905
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 29 $6,043
Symbicort Budesonide/Formoterol Fumarate Brand 20 $5,616
Breyna Budesonide/Formoterol Fumarate Brand 19 $4,787
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 23 $4,765

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$418,384

Of which drugs: $362,886

Medicare patients

253

Average age 73

Services billed

17,188

155 women, 98 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 53%
Ischemic heart disease 21%
Osteoporosis 19%
Diabetes 18%
Depression 18%
Cancer 17%
Chronic kidney disease 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 23 8,492 $252,243

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
$56,656 — —
DUPIXENT
$944 15 —
FASENRA
$572 — —
XOLAIR
$374 25 8,492
TEZSPIRE
$346 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

1,208 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record